Drug profile · INN
loratadine
ALLEREZE
loratadine (ALLEREZE) is a histamine h1 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — loratadine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 8
- Data quality
- 0.89
Quick answer
loratadine (ALLEREZE) is a histamine h1 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is loratadine?
loratadine (ALLEREZE) is a histamine h1 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for loratadine?
ALLEREZE is a marketed brand name for loratadine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of loratadine?
loratadine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.